Salt and Cocrystals Combining Sulfathiazole with Pyrimethamine
(2023) Crystal Growth & Design — Vol. 23, n° 11, p. 7811-7820 (2023)
Files
cg-2023-00626n_Proof_hi.pdf
Open Access - Adobe PDF
- 1.31 MB
Details
- Authors
Tumanov, Nikolay 
Wouters, Johan
- Abstract
- Dihydrofolate reductase inhibitors, such as pyrimethamine, are known to have synergistic effects with sulfonamides. Four new solid forms combining pyrimethamine and sulfathiazole, one cocrystal (pyrimethamine-sulfathiazole (1:1)) and three solvated salt cocrystals (in which pyrimethamine and sulfathiazole are in a 1:2 molar ratio), are determined and characterized. Desolvation of the salt cocrystals leads to either a physical mixture of the starting compounds or the formation of the cocrystal (1:1) with an excess of sulfathiazole. The pyrimethamine sulfathiazole binary phase diagram was determined, which reveals that the pyrimethamine-sulfathiazole (1:2) composition point corresponds to a metastable eutectic. Obtaining this metastable eutectic as a pure powder is therefore rather difficult since it converts to a stable mixture of the (1:1) cocrystal + sulfathiazole. The abovementioned drug–drug multicomponent systems are characterized in terms of thermal stability (by TGA/DSC) and solubility. Both pyrimethamine-sulfathiazole (1:1) cocrystal and pyrimethamine-sulfathiazole (1:2) ethanol-solvated salt cocrystal result in an increase of the parent drugs’ solubility.
- Affiliations
Citations
Bodart, L., Body, J., Tumanov, N., Leyssens, T., & Wouters, J. (2023). Salt and Cocrystals Combining Sulfathiazole with Pyrimethamine. Crystal Growth & Design, 23(11), 7811-7820. https://doi.org/10.1021/acs.cgd.3c00626 (Original work published 2023)